USS Investment Management Ltd Trims Holdings in The Clorox Company (NYSE:CLX)

USS Investment Management Ltd lowered its stake in shares of The Clorox Company (NYSE:CLX - Free Report) by 27.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 40,723 shares of the company's stock after selling 15,442 shares during the period. USS Investment Management Ltd's holdings in Clorox were worth $6,618,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in CLX. Waverly Advisors LLC raised its stake in Clorox by 2.3% during the 4th quarter. Waverly Advisors LLC now owns 34,754 shares of the company's stock worth $5,644,000 after buying an additional 778 shares during the period. Vident Advisory LLC bought a new stake in shares of Clorox during the fourth quarter valued at approximately $456,000. Sone Capital Management LLC acquired a new position in shares of Clorox during the fourth quarter worth approximately $10,248,000. Virtus Investment Advisers Inc. bought a new position in shares of Clorox in the 4th quarter worth $76,000. Finally, WBI Investments LLC acquired a new stake in Clorox in the 4th quarter valued at $806,000. Institutional investors own 78.53% of the company's stock.

Insider Buying and Selling at Clorox

In other Clorox news, Director Pierre R. Breber bought 4,000 shares of Clorox stock in a transaction dated Wednesday, May 7th. The stock was purchased at an average price of $136.57 per share, for a total transaction of $546,280.00. Following the completion of the purchase, the director now directly owns 4,000 shares of the company's stock, valued at approximately $546,280. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.57% of the company's stock.

Analysts Set New Price Targets

Several research firms have weighed in on CLX. Royal Bank of Canada restated a "sector perform" rating and set a $150.00 price objective on shares of Clorox in a report on Thursday, January 30th. Citigroup dropped their price target on shares of Clorox from $165.00 to $150.00 and set a "neutral" rating on the stock in a research report on Monday, April 14th. Barclays cut their price target on Clorox from $134.00 to $129.00 and set an "underweight" rating for the company in a research note on Wednesday, May 7th. Evercore ISI set a $140.00 price objective on Clorox and gave the stock an "underperform" rating in a research note on Tuesday, May 6th. Finally, Morgan Stanley cut their target price on Clorox from $165.00 to $150.00 and set an "equal weight" rating on the stock in a research report on Tuesday, May 6th. Three analysts have rated the stock with a sell rating, eleven have assigned a hold rating and one has assigned a buy rating to the company's stock. According to MarketBeat, Clorox currently has an average rating of "Hold" and a consensus price target of $151.23.

Clorox Stock Performance

Shares of NYSE:CLX traded up $0.12 during mid-day trading on Tuesday, reaching $131.00. The company had a trading volume of 418,255 shares, compared to its average volume of 1,330,499. The Clorox Company has a one year low of $127.60 and a one year high of $171.37. The company has a current ratio of 0.94, a quick ratio of 0.60 and a debt-to-equity ratio of 20.52. The company's 50-day moving average price is $139.35 and its 200-day moving average price is $152.00. The firm has a market cap of $16.15 billion, a price-to-earnings ratio of 35.78, a PEG ratio of 2.62 and a beta of 0.60.

Clorox (NYSE:CLX - Get Free Report) last issued its earnings results on Monday, May 5th. The company reported $1.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.12). The firm had revenue of $1.67 billion during the quarter, compared to the consensus estimate of $1.74 billion. Clorox had a net margin of 6.38% and a return on equity of 316.87%. The business's quarterly revenue was down 8.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.71 earnings per share. As a group, equities research analysts anticipate that The Clorox Company will post 7.15 EPS for the current fiscal year.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.